{
    "id": "dbpedia_6045_2",
    "rank": 25,
    "data": {
        "url": "https://www.bloomberg.com/news/articles/2021-05-27/china-s-sinopharm-publishes-awaited-covid-vaccine-study-details",
        "read_more_link": "",
        "language": "en",
        "title": "China’s Sinopharm Publishes Awaited Covid Vaccine Study Details",
        "top_image": "https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iFc5jibGJsjo/v0/1200x800.jpg",
        "meta_img": "https://assets.bwbx.io/images/users/iqjWHBFdfxIU/iFc5jibGJsjo/v0/1200x800.jpg",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "China",
            "Coronavirus",
            "American Medical Association",
            "Developing Countries",
            "Seychelles",
            "SINOVAC BIOTECH LTD",
            "Regulation",
            "Chile",
            "Hungary",
            "Serbia",
            "technology",
            "business",
            "prognosis"
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2021-05-27T00:00:00",
        "summary": "",
        "meta_description": "Vaccines from China’s Sinopharm successfully contained Covid-19, according to a study published in a prestigious U.S. medical journal, the first time detailed findings from a late-stage trial of a Chinese shot have appeared in the scientific literature.",
        "meta_lang": "en",
        "meta_favicon": "https://www.bloomberg.com/favicon-black.png",
        "meta_site_name": "Bloomberg.com",
        "canonical_link": "https://www.bloomberg.com/news/articles/2021-05-27/china-s-sinopharm-publishes-awaited-covid-vaccine-study-details",
        "text": "Vaccines from China’s Sinopharm successfully contained Covid-19, according to a study published in a prestigious U.S. medical journal, the first time detailed findings from a late-stage trial of a Chinese shot have appeared in the scientific literature.\n\nThe two inactivated vaccines developed by Sinopharm’s vaccine-making unit China National Biotec Group Co. prevented symptomatic infections by 72.8% and 78.1%, largely in-line with what the state-owned drugmaker previously announced. The findings were reported in the May 26 Journal of the American Medical Association."
    }
}